Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
51.42
+2.88 (5.93%)
Jun 3, 2026, 3:41 PM EDT - Market open
Exelixis Employees
Exelixis had 1,077 employees as of December 31, 2025. The number of employees decreased by 70 or -6.10% compared to the previous year.
Employees
1,077
Change (1Y)
-70
Growth (1Y)
-6.10%
Revenue / Employee
$2,205,656
Profits / Employee
$773,836
Market Cap
12.92B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,077 | -70 | -6.10% |
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
EXEL News
- 4 hours ago - Exelixis Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 3 days ago - Exelixis announces results from subgroup analysis of Phase 3 Cabinet trial - TheFly
- 4 days ago - Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 - Business Wire
- 6 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June - Business Wire
- 7 days ago - Exelixis Transcript: Bernstein 42nd Annual Strategic Decisions Conference - Transcripts
- 7 days ago - Caring Men Global Partners with Exelixis to Launch “Strong Caregivers, Stronger Survivors” Caregiver Training Initiative - Business Wire
- 8 days ago - Exelixis Transcript: AGM 2026 - Transcripts
- 12 days ago - Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types - Business Wire